Introduction: Thymic carcinomas are aggressive tumors. Biomarkers and alternative treatment modalities are needed. We studied the expression of p16 and cytogenetic abnormalities of cyclin-dependent kinase inhibitor 2A gene (CDKN2A) and correlated findings with clinical features and outcome in a large cohort of thymic carcinomas.
Introduction
Thymic carcinomas are aggressive tumors that frequently metastasize and recur. Median time to death ranges from 2 to 3.6 years, and 10-year survival ranges from 0% to 67%. [1] [2] [3] In most patients, thymic carcinomas are diagnosed at a high stage, precluding surgical intervention.
complete pathologic response to neoadjuvant therapy in thymic carcinomas, and the percentage of viable tumor ranged between 1% and 95% after neoadjuvant treatment. 7, 8 Therefore, alternative treatment modalities are needed. However, most thymic carcinomas are of the squamous cell carcinoma subtype, 1, 9 for which only very limited alternative treatment modalities are currently available. Tumor stage and complete resection have been recognized as prognostic parameters in thymic carcinomas 2, 3 ; however, only a few biomarkers have been identified for prognosis and decisions regarding treatment of these tumors.
The study of thymic carcinomas is hampered by their paucity, given an incidence of thymic epithelial tumors (TET) of 1 to 5 cases per million population per year. 10 Genetic alterations of these tumors are largely unknown. Petrini et al. identified homozygous 9p21.3 copy number loss (attributed to cyclin-dependent kinase inhibitor 2A gene [CDKN2A]/cyclin-dependent kinase inhibitor 2B gene [CDKN2B] loci) in two of seven thymic carcinomas (28.6%) and two of 20 type B3 thymomas (10%) but in no other thymomas. 11 Copy number loss of CDKN2A/ CDKN2B in these four cases was associated with worse disease-related survival and time to progression. In addition, cases with copy number loss of CDKN2A/ CDKN2B lacked expression of p16.
CDKN2A, a gene that is located on chromosome 9p21.3, encodes p16(INK4a).
12 p16 protein acts through inhibition of CDK4 and CDK6 and is a negative regulator of cell cycle progression. Inactivating mutations alter its inhibitory function on the cell cycle, permitting inappropriate progression through the cell cycle that may lead to uncontrolled tumor cell proliferation. Evidence suggests that loss of p16 expression is a common event in NSCLC; specifically, in one study, 84% of squamous cell carcinomas had loss of p16 expression. 13 In that study loss of p16 expression was also associated with worse survival of the entire study population and specifically of patients younger than 65 years. Similarly, in squamous cell carcinoma of the vagina or oral cavity, patients with p16-negative tumors had worse outcome than patients with p16-positive tumors. 14, 15 Although some evidence suggests that a subset of TETs harbor a CDKN2A deletion and show loss of p16 expression, which are findings that might be associated with worse outcome, 11 the association between p16 expression and CDKN2A deletion with prognosis, stage, and clinical parameters has not been thoroughly investigated in thymic carcinomas. We studied the expression of p16 and cytogenetic abnormalities of its associated gene, CDKN2A, and correlated these findings with clinical parameters and outcome in a large cohort of thymic carcinomas.
Material and Methods

Patients
Surgical pathology files of the Mayo Clinic Rochester were searched for thymic carcinomas . Only patients who underwent a surgical procedure to potentially resect the primary thymic carcinoma and had viable tumor tissue available were included. In a single case material was utilized from a lymph node metastasis that occurred 2 years after resection of the primary thymic carcinoma because there was no viable primary tumor in the resection specimen and tissue from a pretreatment biopsy was not available for further studies. Recurrences were not included. Eighteen cases were previously published. 16 All cases were reviewed by three thoracic pathologists (A.C.R., M.C.A., and E.S.Y.) who agreed on the diagnosis of carcinoma. All thymic carcinomas were subtyped according to the current WHO classification. 17 Tumor size was identified from pathology reports and recorded for completely resected tumors. Thymic carcinomas were staged according to the TNM classification 18 and the staging system that was recently proposed by the International Association for Study of Lung Cancer and the International Thymic Malignancy Interest Group. 19 Medical records were studied. The study was approved by the institutional review board (10-003525).
Immunohistochemistry
Immunohistochemistry was performed with an antibody against p16 (clone E6H4, Ventana Medical Systems, Inc., Tucson, AZ). Percent tumor cell nuclei staining was scored as negative (<1%) or positive (scores 1þ [1%-25%], 2þ [26%-50%], 3þ [51%-75%], and 4þ [>75%]).
FISH
Fluorescence in situ hybridization (FISH) was performed for assessment of the CDKN2A gene (at 9p21) as previously described by using a CDKN2A probe (Abbott Molecular/Vysis, Des Plaines, IL) consisting of CDKN2A DNA labeled with SpectrumOrange and D9Z1 DNA labeled with SpectrumGreen. 20 An enumeration strategy was used for assessment of the CDKN2A gene. A signal pattern of two red and two green signals indicated two intact CDKN2A loci on chromosome 9; one red and two green signals indicated heterozygous deletion of CDKN2A, and no red and two green signals indicated a homozygous deletion of CDKN2A. Two technologists independently scored a total of 200 tumor cells for each specimen.
Statistical Analysis
For statistical analysis, thymic carcinomas were categorized as well differentiated or moderately differentiated Overall survival (OS) and recurrence and metastasis-free survival were estimated at 2 years after surgery with the Kaplan-Meier method and compared with p16 expression and FISH by using likelihood ratio tests from Cox proportional hazards regression models. Estimates at 2 years and 95% confidence intervals (rather than at 5 or 10 years) were reported on account of sample size, timing of events, and available follow-up time.
Kaplan-Meier curves are presented to illustrate the entire follow-up period. Data were also compared between positive and negative p16 expression groups among the subset of patients with thymic squamous cell carcinoma by using the methods already outlined, but statistical testing between CDKN2A groups in this subset was not performed on account of small sample size (two deleted versus 11 not deleted). Limited multivariable analyses were also performed by using Cox proportional hazards regression models from which hazard ratios and 95% profile likelihood-based confidence intervals were reported. p Values less than 0.05 were considered statistically significant. All analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, NC), and figures were generated by using R software (R Foundation for Statistical Computing, Vienna, Austria). 21 
Results
Thymic carcinomas from 27 patients (including 15 men [55.6%]) with a median age of 51.7 years (range 
Loss of p16 Expression Is Associated with Worse Recurrence and Metastasis-Free Survival in Thymic Carcinomas
Results of testing for p16 expression were available for 26 patients; one sample was exhausted of tissue. The p16 protein was not expressed in 12 of 26 patients (46.2%) (Fig. 1A-D) and expressed in 14 (53.8%), including with scores of 1þ (n ¼ 3 [11 
The correlation of p16 expression with Figure 1 . A poorly differentiated thymic squamous cell carcinoma (hematoxylin and eosin [HE] staining) (A) lacks expression of p16 (B and C) and shows homozygous deletion of CDKN2A (fluorescence in situ hybridization, two green signals and no red signal) (D). Another poorly differentiated thymic squamous cell carcinoma (HE staining) (E) with a p16 score of 2þ (F and G) shows heterozygous deletion of CDKN2A (two green signals and one red signal) (H). A thymic carcinoma, undifferentiated carcinoma subtype (HE staining) (I) with a p16 score of 3þ (J and K) shows normal (two) copies of CDKN2A (two green and two red signals) (L). A moderately differentiated thymic squamous cell carcinoma (HE staining) (M) with a p16 score of 3þ (N and O) shows additional copies of chromosome 9 (three green and three red signals) (P). Arrows point at representative cells. Magnification, Â40 (A, B, E, F, I, J, M, and N), Â400 (C, G, K, and O) , and Â1000 (oil) (D, H, L, and P).
demographics, symptoms at presentation, resection status, and tumor characteristics is summarized in Table 1 . Patients with thymic carcinoma lacking p16 expression tended to be younger (median age 45.5 versus 58.6 years for p16-negative versus p16-positive patients, p ¼ 0.05 [ Fig. 2A] p16 Expression Correlates with Homozygous CDKN2A Deletion in Thymic Carcinomas CDKN2A analysis was successfully performed by FISH in 22 patients. The remaining cases had either insufficient material (n ¼ 3) or hybridization failure (n ¼ 2). Four of 22 tumors (18.2%) showed homozygous CDKN2A deletion (Fig. 1A-D) . Eighteen of 22 cases (81.8%) harbored normal (two) CDKN2A copies (n ¼ 10, 45.5% [ Fig. 1I-L] ) or had additional (more than two) copies (n ¼ 6 [27.3%] [ Fig. 1M-P] ) or a single copy deletion (n ¼ 2 [9.1%] [ Fig. 1E-H] ) of CDKN2A.
Loss of p16 expression correlated with homozygous CDKN2A deletion (p ¼ 0.02 [ Table 2 ]). All four cases with CDKN2A homozygous deletion lacked p16 expression (Fig. 1A-D) . The remaining five of nine p16-negative thymic carcinomas (55.6%) had either two copies (n ¼ 3) or additional copies (n ¼ 2) of CDKN2A. No CDKN2A Figure 2 . Association between age and p16 expression and homozygous deletion of cyclin-dependent kinase inhibitor 2A gene (CDKN2A) from 21 patients with available p16 expression and CDKN2A fluorescence in situ hybridization data. Each circle represents an individual patient. All patients with homozygous CDKN2A deletion (red cross) also had loss of p16 expression.
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p16 Loss, CDKN2A Deletion in Thymic Carcinoma Figure 3 . Kaplan-Meier curves for recurrence and metastasis-free survival and overall survival for the entire thymic carcinoma cohort (A and B) and thymic squamous cell carcinomas (C-F) based on p16 expression and homozygous cyclin-dependent kinase inhibitor 2A gene (CDKN2A) deletion.
homozygous deletion was identified in a tumor that expressed p16.
To evaluate whether p16 expression and/or CDKN2A gene status might be different after neoadjuvant systemic therapy, available pretreatment biopsy specimens that had sufficient tissue for further study (five of eight patients) were evaluated. The results are summarized in Table 3 . In two cases preneoadjuvant biopsy specimens and postneoadjuvant specimens showed the same results for p16 expression and CDKN2A gene status. In one case p16 expression was different between the preneoadjuvant therapy and postneoadjuvant therapy biopsy specimen; CDKN2A gene status was different in three cases.
Homozygous CDKN2A Deletion Is Associated with Younger Age at Surgery in Thymic Carcinomas
Correlations of CDKN2A FISH results (homozygous deletion versus other) with demographics, symptoms at presentation, and resection status of the study population and tumor characteristics are summarized in Table 4 . Patients with thymic carcinomas showing homozygous CDKN2A deletion were significantly younger than other patients with thymic carcinoma (median age 34.0 versus 54.2 years, p ¼ 0.0005 [ Fig. 2A]) . Patients with tumors having homozygous CDKN2A deletion tended to have a worse recurrence and metastasis-free survival than patients with tumors without homozygous deletion of CDKN2A (HR for deletion versus nondeletion ¼ 3.48, 95% CI: 0.72-13.39, p ¼ 0.11).
Loss of p16 Expression Is Associated with Worse Outcome in Thymic Squamous Cell Carcinomas
Because loss of p16 expression has been associated with worse outcome in squamous cell carcinomas of other organs 14, 15 and given that squamous cell carcinoma is the most common subtype of thymic carcinoma, 9 we evaluated p16 expression and CDKN2A gene status of thymic squamous cell carcinomas separately (Tables 1 and 4 ). Patients with thymic squamous cell carcinoma lacking p16 expression were significantly younger at time of surgery than patients with tumors expressing p16 (median age 48.9 versus 61.0 years, p ¼ 0.006 [ Fig. 2B] ). Although patients with thymic squamous cell carcinomas showing homozygous CDKN2A deletion (n ¼ 2) were overall younger at time of surgery than patients with tumors not harboring that deletion (n ¼ 11) (ages 32 and 36 versus a median of 57.5 years [ Fig. 2B] ) statistical analysis could not be performed because of the small number of thymic squamous cell carcinoma with homozygous CDKN2A deletion. In patients with thymic squamous cell carcinomas, loss of p16 expression was associated with worse recurrence and metastasis-free survival (HR for p16-positive versus p16-negative patients ¼ 0.05, 95% CI: 0-0.43, p ¼ 0.006 [ Fig. 3C] ) and worse OS (HR for p16-positive versus p16-negative patients ¼ 0, 95% CI: 0-0.20, p ¼ 0.0009 [ Fig. 3D] ) when compared with patients with p16 expression. Although patients with homozygous deletion of CDKN2A showed worse recurrence and metastasisfree survival and OS in comparison with patients without CDKN2A homozygous deletion (Fig. 3E and F) , given the small number of patients with thymic squamous cell carcinoma with homozygous CDKN2A deletion, statistical analysis could not be performed.
Discussion
Our study shows that loss of p16 expression is associated with worse recurrence and metastasis-free survival and OS in thymic squamous cell carcinomas. Patients with thymic squamous cell carcinomas with CDKN2A deletion also tended to have worse OS. Moreover, loss of May 2017 p16 Loss, CDKN2A Deletion in Thymic Carcinoma p16 expression was associated with worse recurrence and metastasis-free survival and a trend toward worse OS in the entire thymic carcinoma cohort. In addition, loss of p16 expression was associated with younger age of patients with thymic squamous cell carcinoma; homozygous CDKN2A deletion in thymic squamous cell carcinoma also tended to occur in younger patients. Furthermore, homozygous CDKN2A deletion was associated with younger age in the entire thymic carcinoma cohort; patients with p16-negative thymic carcinomas tended to be of younger age as well. Our findings suggest that loss of p16 expression and homozygous CDKN2A deletion might be predictive of worse outcome specifically in thymic squamous cell carcinomas, are independent of known prognostic parameters such as staging and complete resection, and are more common abnormalities in younger patients with that disease. Petrini et al. identified homozygous 9p21.3 copy number loss in two of seven thymic carcinomas (28.6%), although their subtype was not specified. 11 In our series of 22 thymic carcinomas with available tissue for FISH studies, only four thymic carcinomas (18%) showed homozygous deletion of the CDKN2A gene. The slightly lower incidence of homozygous deletion of CDKN2A might be due to the inclusion of different subtypes of thymic carcinomas in our study. In our study, homozygous deletion of CDKN2A was identified most commonly in thymic carcinomas of the squamous cell subtype (two of four) but was also identified in one adenocarcinoma and one lymphoepithelioma-like carcinoma.
In the study by Petrini et al. of 59 TETs, the four patients with homozygous 9p21.3 copy number loss (two B3 thymomas and two thymic carcinomas) had worse disease-related survival and time to progression. 11 In NSCLC, loss of p16 expression was a common event that occurred in 84% of squamous cell carcinomas and was also associated with worse survival. 13 We showed that patients with loss of p16 expression have worse recurrence and metastasis-free survival and OS in thymic squamous cell carcinoma. Although the two May 2017 p16 Loss, CDKN2A Deletion in Thymic Carcinomapatients with thymic squamous cell carcinoma with CDKN2A deletion also tended to have a worse OS, the number of patients is too small to draw firm conclusions. Our findings are not surprising given that CDKN2A encodes p16, a tumor suppressor with an inhibitory action on cell cycle progression. Our results suggest that loss of p16 expression and homozygous deletion of CDKN2A might be useful predictors of outcome in thymic carcinoma and specifically in those of the squamous cell subtype.
Given that CDKN2A encodes the p16 protein, it is not surprising that we identified a correlation between loss of p16 expression and homozygous CDKN2A deletion in thymic carcinomas. Similarly, Petrini et al. 11 found that copy number loss of CDKN2A correlated with lack of expression of p16 in TET. In our study, however, only four of nine (44%) patients lacking p16 expression in the tumor cells had homozygous CDKN2A deletion. Five additional patients with loss of p16 expression had either the normal two copies of CDKN2A or additional copies. Therefore, mechanisms other than homozygous deletion of CDKN2A are likely responsible for loss of p16 expression in some thymic carcinomas. Such mechanisms could include point mutations in the CDKN2A gene or epigenetic silencing of the CDKN2A gene (e.g., hypermethylation of the CDKN2A promoter sequence). 12 In a study of lung carcinomas p16 has been shown to be inactivated in 72% of squamous cell carcinomas, most commonly by homozygous deletion (29%) but also by epigenetic silencing through promotor methylation (21%), inactivating mutation (18%), and exon 1b skipping (4%). 22 Alterations in the CDKN2A gene may also be important for targeted therapy. For instance, in vitro studies have shown that an inhibitor targeting the CDK4/6 protein, was an effective inhibitor of CDKN2A-mutated gastric cancer cell lines. 23 In these studies the CDK4/6 inhibitor selectively inhibited cell growth, migration, invasion, and colony formation of gastric cancer cells with CDKN2A mutation. Similarly, in vivo studies using a xenograft gastric cancer mouse model showed significantly smaller CDKN2A-mutated gastric cancer tumors in mice treated with CDK4/6 inhibitor than in sham-treated mice. Therefore, CDK4/6 inhibitor might be a potential therapeutic agent for CDKN2A-mutated cancers, including thymic carcinomas.
We determined that loss of p16 expression and homozygous CDKN2A deletion are associated with younger age of patients, specifically in patients with squamous cell carcinoma subtype. Evidence suggests age-related differences in methylation levels of the CDKN2A promotor in NSCLC. 24 In NSCLC, patients who were younger had lower CDKN2A promoter methylation levels than older patients. Expression levels of p16 were also slightly higher in tumors of older patients than in tumors of younger patients. In addition, younger patients with CDKN2A promoter hypermethylation had a significantly shorter time to recurrence and shorter survival, a phenomenon that was not seen in older patients.
Because systemic neoadjuvant therapy might alter p16 expression and/or CDKN2A gene status, p16 immunostaining and FISH studies were performed on available pretreatment biopsy specimens. Our findings show that p16 expression status differed between preneoadjuvant therapy and postneoadjuvant therapy biopsy specimens in only one case (20%). This discrepancy might be due to sampling bias (as the biopsy was a small needle core biopsy) or might even be due to differences in specimen fixation. In three cases (60%) there was a change in cytogenetic findings. Although sampling or scoring bias might play a role, at least in a subset of cases, these findings could also indicate that at least in some cases, pretreatment systemic therapy might alter the genetic constellation of the tumor. Conceivably, these changes may also occur between primary tumor and metastasis. Because of the low number of pretreatment biopsy specimens, it is not possible to statistically evaluate the impact of the differences in p16 expression and CDKN2A gene status in this study. However, although there might be alterations in expression of p16 and the CDKN2A status between pretreatment biopsy specimen and resection specimen, we believe that our data are of prognostic value when evaluated at time of surgery. Although our series of p16 expression and CDKN2A FISH studies is the largest in thymic carcinomas, the overall number of 27 cases is relatively small. Therefore, the statistical results might not be very stable. In addition, multiple histologic subtypes of this tumor might contribute to some heterogeneity of results. Therefore, larger, possibly multi-institutional, studies are needed, for instance, to investigate whether CDKN2A homozygous deletion might also be a prognostic parameter in thymic carcinomas.
In conclusion, loss of expression of p16 and homozygous deletion of CDKN2A are promising prognostic biomarkers for thymic carcinomas, specifically those of squamous cell subtype. Moreover, in thymic squamous cell carcinomas, loss of p16 expression is associated with younger age of patients. On the basis of our findings, CDK4/6 inhibitors might be considered for targeted therapy, but further functional studies are needed to better understand their effect on this disease.
